RxDoctor Payments DataLook up a doctor →

Aaron Hoover, MD

Dermatopathology · Greeley, CONPI 1609883081

Payments from drug & device makers

$7,194in general payments, 2019–2025

Across 336 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$974
  • Sun Pharmaceutical Industries Inc.$686
  • Sanofi$685
  • Johnson & Johnson$525
  • Novartis$484
  • Regeneron Healthcare Solutions, Inc.$478
  • plus $3K from 26 others

What the payments were for

  • Food & beverage$6,65793%
  • Education$5377%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few dermatopathology providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,155,471
Medicare patients
1,374
Services billed
25,948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab65$256,392
Dupixent SyringeDupilumab26$99,713
Taltz AutoinjectorIxekizumab12$81,329
JubliaEfinaconazole12$17,766
Ketoconazole510$8,793
Fluorouracil102$5,597
Clobetasol Propionate71$2,726
Tavaborole20$2,505
Metronidazole26$1,773
Tacrolimus21$1,582
Imiquimod52$1,473
CiclopiroxCiclopirox Olamine56$1,174
Minoxidil80$739
Ciclopirox19$735
Triamcinolone Acetonide107$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$174$17,76612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few dermatopathology providers in Coloradoon file to place this against a meaningful peer group, so we don't.

Other dermatopathology in Greeley

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →